Biotechnology Sector Trends and Investor Sentiment: As a clinical-stage biopharmaceutical company, CTMX's stock performance is highly sensitive to overall market sentiment towards the biotech sector, especially for companies with drug candidates in early development. Funding and investor confidence are crucial for its R&D activities.

Regulatory Environment and FDA Approvals: CytomX Therapeutics' success hinges on positive outcomes from clinical trials and subsequent regulatory approvals (e.g., from the FDA) for its innovative cancer therapies. Delays, unfavorable trial results, or regulatory hurdles can significantly impact its stock value.

Inflation, Interest Rates, and Global Growth Forecasts: High inflation and rising interest rates can increase borrowing costs for CTMX, which may rely on external capital for its extensive research and development. Downgrades in global growth forecasts can also dampen investor appetite for higher-risk, growth-oriented biotech stocks.